{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:18Z","timestamp":1792025178836,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Papillary craniopharyngioma is a rare entity, demonstrating BRAF-V600E mutations in approximately 95% of patients. Recently, a phase 2 trial of patients treated with surgery and BRAF\/MEKi demonstrated 91% reduction in residual tumor volume. This study allowed for additional treatments at the discretion of the treatment team without reporting subsequent rates of endocrinopathy or visual decline. We aimed to evaluate the possibility of employing BRAF\/MEKi without the need for adjuvant radiotherapy therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective report of two patients treated with resection and BRAF\/MEKi without additional treatment were analyzed. Patient demographics, treatment characteristics, pre- and post-treatment radiographic volumes, adverse events, and endocrinologic and visual outcomes, were recorded and analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two patients underwent subtotal resection followed by BRAF\/MEKi without adjuvant treatment. Mean length of BRAF therapy was 21.4 months and MEKi therapy was 12.94 months. Mean preoperative nodule volume was 0.33\u00a0cm [3] and 2.29\u00a0cm [3] and cystic volume was 5.04\u00a0cm [3] and 6.18\u00a0cm [3] in case 1 and case 2, respectively. Neither patient received radiation. Grade 3 cardiotoxicity developed in case 1 after 6.5 months, with function recovering completely following discontinuation of MEKi. BRAF therapy was discontinued electively after 23.5 months. The second patient remains on dual inhibition therapy without toxicity. For these cases, post-treatment nodule volumes are 0.07\u00a0cm [3] (98.4% reduction) and 0.04\u00a0cm [3] (99.2% reduction), respectively, and cystic volume 0.0\u00a0cm [3] in both patients. Progression free survival is 100% with a mean follow up of 36-months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Utilizing surgery and BRAF\/MEKi without adjuvant radiation, we demonstrate excellent disease control with reversible toxicity. Avoiding additional treatments may spare vital functions and unnecessary procedures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-04969-3","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:55:44Z","timestamp":1740052544000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Papillary craniopharyngioma management in the era of BRAF and MEK inhibition"],"prefix":"10.1007","volume":"173","author":[{"given":"Mark","family":"Damante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santino","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kreatsoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luma","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrima","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Prevedello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"1","key":"4969_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00000478-198401000-00006","volume":"8","author":"F Giangaspero","year":"1984","unstructured":"Giangaspero F, Burger PC, Osborne DR, Stein RB (1984) Suprasellar papillary squamous epithelioma (papillary craniopharyngioma). Am J Surg Pathol Jan 8(1):57\u201364. https:\/\/doi.org\/10.1097\/00000478-198401000-00006","journal-title":"Am J Surg Pathol Jan"},{"issue":"2","key":"4969_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3171\/jns.1995.83.2.0206","volume":"83","author":"TB Crotty","year":"1995","unstructured":"Crotty TB, Scheithauer BW, Young WF Jr. et al (1995) Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg Aug 83(2):206\u2013214. https:\/\/doi.org\/10.3171\/jns.1995.83.2.0206","journal-title":"J Neurosurg Aug"},{"issue":"2","key":"4969_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE et al (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet Feb 46(2):161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet Feb"},{"issue":"8","key":"4969_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"2","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol Aug 2(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol Aug"},{"issue":"3","key":"4969_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-010-0265-y","volume":"101","author":"ME Sughrue","year":"2011","unstructured":"Sughrue ME, Yang I, Kane AJ et al (2011) Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma. J Neurooncol Feb 101(3):463\u2013476. https:\/\/doi.org\/10.1007\/s11060-010-0265-y","journal-title":"J Neurooncol Feb"},{"issue":"1","key":"4969_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-012-0806-7","volume":"108","author":"A Schoenfeld","year":"2012","unstructured":"Schoenfeld A, Pekmezci M, Barnes MJ et al (2012) The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol May 108(1):133\u2013139. https:\/\/doi.org\/10.1007\/s11060-012-0806-7","journal-title":"J Neurooncol May"},{"key":"4969_CR7","doi-asserted-by":"publisher","first-page":"1180993","DOI":"10.3389\/fonc.2023.1180993","volume":"13","author":"C Friedrich","year":"2023","unstructured":"Friedrich C, Boekhoff S, Bischoff M et al (2023) Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients-results of KRANIOPHARYNGEOM 2007. Front Oncol 13:1180993. https:\/\/doi.org\/10.3389\/fonc.2023.1180993","journal-title":"Front Oncol"},{"key":"4969_CR8","doi-asserted-by":"publisher","unstructured":"Marcus HJ, Rasul FT, Hussein Z et al Craniopharyngioma in children: trends from a third consecutive single-center cohort study. J Neurosurg Pediatr Dec 20 2019:1\u20139. https:\/\/doi.org\/10.3171\/2019.10.PEDS19147","DOI":"10.3171\/2019.10.PEDS19147"},{"issue":"5","key":"4969_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1470-2045(23)00146-8","volume":"24","author":"TE Merchant","year":"2023","unstructured":"Merchant TE, Hoehn ME, Khan RB et al (2023) Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study. Lancet Oncol May 24(5):523\u2013534. https:\/\/doi.org\/10.1016\/S1470-2045(23)00146-8","journal-title":"Lancet Oncol May"},{"issue":"5","key":"4969_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ijrobp.2021.02.045","volume":"1","author":"RB Jimenez","year":"2021","unstructured":"Jimenez RB, Ahmed S, Johnson A et al (2021) Proton Radiation Therapy for Pediatric Craniopharyngioma. Int J Radiat Oncol Biol Phys Aug 1(5):1480\u20131487. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.045","journal-title":"Int J Radiat Oncol Biol Phys Aug"},{"issue":"2","key":"4969_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ijrobp.2014.05.051","volume":"1","author":"AJ Bishop","year":"2014","unstructured":"Bishop AJ, Greenfield B, Mahajan A et al (2014) Proton Beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys Oct 1(2):354\u2013361. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.05.051","journal-title":"Int J Radiat Oncol Biol Phys Oct"},{"key":"4969_CR12","doi-asserted-by":"publisher","unstructured":"Ravindra VM, Okcu MF, Ruggieri L et al Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: long-term analysis of progression-free survival and morbidity. J Neurosurg Pediatr May 28 2021:1\u20138. https:\/\/doi.org\/10.3171\/2020.11.PEDS20803","DOI":"10.3171\/2020.11.PEDS20803"},{"key":"4969_CR13","doi-asserted-by":"publisher","unstructured":"Bischoff M, Khalil DA, Frisch S et al (2024) Outcome after Modern Proton Beam Therapy in Childhood Craniopharyngioma: results of the prospective Registry Study KiProReg. Int J Radiat Oncol Biol Phys Mar 15. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.015","DOI":"10.1016\/j.ijrobp.2024.03.015"},{"issue":"7","key":"4969_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/neuonc\/noq007","volume":"12","author":"MJ Dougherty","year":"2010","unstructured":"Dougherty MJ, Santi M, Brose MS et al (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol Jul 12(7):621\u2013630. https:\/\/doi.org\/10.1093\/neuonc\/noq007","journal-title":"Neuro Oncol Jul"},{"issue":"6892","key":"4969_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"27","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nat Jun 27(6892):949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nat Jun"},{"issue":"2","key":"4969_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"13","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S et al (2023) BRAF-MEK inhibition in newly diagnosed Papillary Craniopharyngiomas. N Engl J Med Jul 13(2):118\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2213329","journal-title":"N Engl J Med"},{"issue":"4","key":"4969_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","volume":"26","author":"AL Lin","year":"2023","unstructured":"Lin AL, Tabar V, Young RJ, Geer EB (2023) Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituit Aug 26(4):482\u2013487. https:\/\/doi.org\/10.1007\/s11102-023-01339-y","journal-title":"Pituit Aug"},{"issue":"3","key":"4969_CR18","doi-asserted-by":"publisher","first-page":"e17948","DOI":"10.1371\/journal.pone.0017948","volume":"29","author":"D Dias-Santagata","year":"2011","unstructured":"Dias-Santagata D, Lam Q, Vernovsky K et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One Mar 29(3):e17948. https:\/\/doi.org\/10.1371\/journal.pone.0017948","journal-title":"PLoS One Mar"},{"issue":"1","key":"4969_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0304-419x(03)00016-7","volume":"5","author":"KE Mercer","year":"2003","unstructured":"Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta Jun 5(1):25\u201340. https:\/\/doi.org\/10.1016\/s0304-419x(03)00016-7","journal-title":"Biochim Biophys Acta Jun"},{"issue":"2","key":"4969_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT et al (2018) Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol Feb 19(2):181\u2013193. https:\/\/doi.org\/10.1016\/S1470-2045(18)30015-9","journal-title":"Lancet Oncol Feb"},{"issue":"9\u201310","key":"4969_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000515347","volume":"93","author":"A Bereket","year":"2020","unstructured":"Bereket A (2020) Postoperative and long-term endocrinologic complications of Craniopharyngioma. Horm Res Paediatr 93(9\u201310):497\u2013509. https:\/\/doi.org\/10.1159\/000515347","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"4969_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","volume":"7","author":"HL Muller","year":"2019","unstructured":"Muller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S, Craniopharyngioma (2019) Nat Rev Dis Primers Nov 7(1):75. https:\/\/doi.org\/10.1038\/s41572-019-0125-9","journal-title":"Nat Rev Dis Primers Nov"},{"key":"4969_CR23","doi-asserted-by":"publisher","unstructured":"Welsh SJ, Corrie PG (Mar 2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122\u2013136. https:\/\/doi.org\/10.1177\/1758834014566428","DOI":"10.1177\/1758834014566428"},{"issue":"1","key":"4969_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10143-023-02232-9","volume":"8","author":"R Prieto","year":"2023","unstructured":"Prieto R, Barrios L, Pascual JM (2023) Preoperative MRI diagnosis of papillary craniopharyngiomas: the revealing clues. Neurosurg Rev Dec 8(1):8. https:\/\/doi.org\/10.1007\/s10143-023-02232-9","journal-title":"Neurosurg Rev Dec"},{"issue":"1 Suppl","key":"4969_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/ped.2007.106.1.3","volume":"106","author":"S Puget","year":"2007","unstructured":"Puget S, Garnett M, Wray A et al (2007) Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg Jan 106(1 Suppl):3\u201312. https:\/\/doi.org\/10.3171\/ped.2007.106.1.3","journal-title":"J Neurosurg Jan"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04969-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:30:00Z","timestamp":1745915400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4969"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04969-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB approval not required for less than three patient series at our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required. Patient anonymity maintained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}